Cargando…
A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach
Laryngeal cancer (LC) as one of common malignant tumors in the head and neck region accounted for 1% to 5% of new cancer cases and was ranked as the third otolaryngology cancer. However, some patients with LC were diagnosed at the advanced stage, which can cause delayed diagnosis and treatment. It i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878607/ https://www.ncbi.nlm.nih.gov/pubmed/35212275 http://dx.doi.org/10.1097/MD.0000000000028820 |
_version_ | 1784658699317411840 |
---|---|
author | Wu, Xue Liu, Yongting Ao, Huaixuan Yang, Peng Zhu, Zhitu |
author_facet | Wu, Xue Liu, Yongting Ao, Huaixuan Yang, Peng Zhu, Zhitu |
author_sort | Wu, Xue |
collection | PubMed |
description | Laryngeal cancer (LC) as one of common malignant tumors in the head and neck region accounted for 1% to 5% of new cancer cases and was ranked as the third otolaryngology cancer. However, some patients with LC were diagnosed at the advanced stage, which can cause delayed diagnosis and treatment. It is an urgent task to seek effective biomarkers for the early diagnosis of LC aimed at alleviating suffering. A combination of dried blood spot sampling and direct infusion mass spectrometry technology was applied to 39 patients with LC and 53 healthy individuals. Multiple algorithms towards 93 metabolites including amino acids and carnitine/acylcarnitines were run for selecting differential metabolites. Furthermore, leave-one-out cross-validation method was used to evaluate diagnostic performance of selected metabolite biomarkers. A biomarker panel consisting of arginine, proline, hexacosanoic carnitine, ornithine /citrulline, and 3-hydroxy-octadecenoylcarnitine exhibited potential to distinguish patients with LC from healthy individuals, with a sensitivity of 0.8974 and a specificity of 0.8302 in leave-one-out cross-validation model. The metabolomic analysis of LC patients is beneficial to screen disease-associated biomarkers and develop new diagnostic approaches. |
format | Online Article Text |
id | pubmed-8878607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-88786072022-02-28 A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach Wu, Xue Liu, Yongting Ao, Huaixuan Yang, Peng Zhu, Zhitu Medicine (Baltimore) 5100 Laryngeal cancer (LC) as one of common malignant tumors in the head and neck region accounted for 1% to 5% of new cancer cases and was ranked as the third otolaryngology cancer. However, some patients with LC were diagnosed at the advanced stage, which can cause delayed diagnosis and treatment. It is an urgent task to seek effective biomarkers for the early diagnosis of LC aimed at alleviating suffering. A combination of dried blood spot sampling and direct infusion mass spectrometry technology was applied to 39 patients with LC and 53 healthy individuals. Multiple algorithms towards 93 metabolites including amino acids and carnitine/acylcarnitines were run for selecting differential metabolites. Furthermore, leave-one-out cross-validation method was used to evaluate diagnostic performance of selected metabolite biomarkers. A biomarker panel consisting of arginine, proline, hexacosanoic carnitine, ornithine /citrulline, and 3-hydroxy-octadecenoylcarnitine exhibited potential to distinguish patients with LC from healthy individuals, with a sensitivity of 0.8974 and a specificity of 0.8302 in leave-one-out cross-validation model. The metabolomic analysis of LC patients is beneficial to screen disease-associated biomarkers and develop new diagnostic approaches. Lippincott Williams & Wilkins 2022-02-25 /pmc/articles/PMC8878607/ /pubmed/35212275 http://dx.doi.org/10.1097/MD.0000000000028820 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 5100 Wu, Xue Liu, Yongting Ao, Huaixuan Yang, Peng Zhu, Zhitu A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach |
title | A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach |
title_full | A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach |
title_fullStr | A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach |
title_full_unstemmed | A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach |
title_short | A metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach |
title_sort | metabolomics strategy to identify potential biomarkers associated with human laryngeal cancer based on dried blood spot mass spectrometry approach |
topic | 5100 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878607/ https://www.ncbi.nlm.nih.gov/pubmed/35212275 http://dx.doi.org/10.1097/MD.0000000000028820 |
work_keys_str_mv | AT wuxue ametabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT liuyongting ametabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT aohuaixuan ametabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT yangpeng ametabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT zhuzhitu ametabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT wuxue metabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT liuyongting metabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT aohuaixuan metabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT yangpeng metabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach AT zhuzhitu metabolomicsstrategytoidentifypotentialbiomarkersassociatedwithhumanlaryngealcancerbasedondriedbloodspotmassspectrometryapproach |